# KKR Genetic Disorder L.P. — capital_raise [announced]
Source: sec.gov · situation sit_3bcf6ae0b740ae02af7e · public 3210208535311199709 · retrieved 2026-08-20T13:22:14.947Z

## Overview
BridgeBio Pharma, Inc. is a pharmaceutical company engaged in the development of treatments for genetic disorders.

KKR Genetic Disorder L.P. sold 5,000,000 shares of common stock of BridgeBio Pharma, Inc. in an underwritten public offering on August 17, 2026. The shares were sold at a net price of $77.415 per share to KKR Genetic Disorder L.P., with William Blair & Company, L.L.C., Goldman Sachs & Co. LLC, and KKR Capital Markets LLC serving as representatives of the underwriters. Following the offering, KKR Genetic Disorder L.P. ceased to be a beneficial owner of more than 5% of BridgeBio's common stock.

## Terms
- Counterparty: William Blair & Company, L.L.C., Goldman Sachs & Co. LLC, KKR Capital Markets LLC (underwriters) · Consideration: cash · Price/share: $77.415

## Key dates
- Announced 2026-08-17

## Timeline
- 2026-08-17 · SCHEDULE 13D/A (0001140361-26-033404): SCHEDULE 13D/A - KKR Genetic Disorder L.P. — *BridgeBio Pharma, Inc. is a pharmaceutical company engaged in the development of treatments for genetic disorders.* KKR Genetic Disorder L.P. sold 5,000,000 shares of common stock of BridgeBio Pharma, Inc. in an underwritten public offering on August 17, 2026. The shares were sold at a net price of $77.415 per share to KKR Genetic Disorder L.P., with William Blair & Company, L.L.C., Goldman Sachs & Co. LLC, and KKR Capital Markets LLC serving as representatives of the underwriters. Following the offering, KKR Genetic Disorder L.P. ceased to be a beneficial owner of more than 5% of BridgeBio's common stock.
  https://www.sec.gov/Archives/edgar/data/1780408/0001140361-26-033404.txt

## Citations
- 0001140361-26-033404 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000114036126033404